pharma · Motor fluctuations in advanced Parkinson’s disease · Non Cystic Fibrosis Bronchiectasis
ZAMBON S.P.A
Zambon SpA
Zambon SpA is a pharma organization headquartered in EU. Primary therapeutic focus areas include Motor fluctuations in advanced Parkinson’s disease, Non Cystic Fibrosis Bronchiectasis. NovaPharmaNews links 3 clinical pro
IT HQ
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- IT
- Employees
- 8
- Programs
- 0
- Drugs
- 5
- Patents
- 0
CMS
Phase 3 · small molecule · Non Cystic Fibrosis Bronchiectasis
CMS for Non Cystic Fibrosis Bronchiectasis is a Phase 3 program (small_molecule) at Zambon SpA with 1 ClinicalTrials.gov record(s).
Internal code Z7224L01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zambon SpA
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non Cystic Fibrosis Bronchiectasis
- Status
- completed
- Trials
- 1